iRhythm Technologies provides diagnostic monitoring solutions that facilitate the early diagnosis and treatment of cardiac arrhythmia.
iRhythm provides innovative and cost-effective diagnostic monitoring solutions that facilitate early diagnosis and treatment decisions, with the goal of ultimately improving patient health outcomes and reducing wasteful healthcare spending. Its flagship product, the Zio® Patch, is designed to optimize and simplify the diagnosis of cardiac arrhythmias. Zio® Patch is the smallest, lightest, least conspicuous cardiac arrhythmia diagnostic available and is indicated for up to 14-day monitoring.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 21, 2020 | Post-IPO Secondary | $220M | — | — | — | Detail |
Sep 11, 2019 | Post-IPO Equity | $115M | — | — | — | Detail |
Oct 20, 2016 | IPO | $107M | — | — | — | Detail |
May 22, 2014 | Series E | $27.34M | 2 | Novo Holdings | — | Detail |
Apr 10, 2013 | Series D | $16M | 5 | Norwest Venture Partners | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Oct 10, 2019
Parsley Health
|
Series B | $26M | Health Care | — |
Apr 21, 2016
Sibly
|
Seed | — | Health Care | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Novo Holdings | Yes | Series E |
California HealthCare Foundation | Yes | Series Unknown |
Norwest Venture Partners | — | Series E |
Kaiser Permanente Ventures | — | Series D |
New Leaf Venture Partners | — | Series D |
Stanford University | — | Series D |
Synergy Life Science Partner | — | Series D |
Mohr Davidow Ventures | — | Private Equity(PE) |
St. Jude Medical | — | Series Unknown |
TBJ Investments | — | Series A |